Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aqualief
- Development stage
- Unknown
- Administration
- Oral
01
Overview
Aqualief is an oral dietary supplement formulated as a mucoadhesive tablet, developed to help stabilize saliva flow and maintain neutral pH in the oral cavity, thereby improving the acid buffering capacity of saliva. It is intended for the management of **xerostomia** (dry mouth) of various etiologies. The tablet is specifically designed for patients with mild-to-moderate xerostomia (RTOG/EORTC grade 1-2). The mechanism of action is not fully elucidated, but the supplement acts locally in the oral cavity to alleviate symptoms of dry mouth by supporting saliva production and pH buffering[1].
- Brand names
- Aqualief
Beyond the preview
Go deeper on aqualief.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aqualief.